The Switch from Latent to Productive Infection in Epstein-Barr Virus-Infected B Cells Is Associated with Sensitization to NK Cell Killing

Por Pappworth, Isabel Y., Wang, Eddie C., Rowe, Martin
Publicado em 2007

Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21)

Por Pappworth, Isabel Y., Kulik, Liudmila, Haluszczak, Catherine, Reuter, Jason W., Holers, V. Michael, Marchbank, Kevin J.
Publicado em 2009

Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression

Por Pappworth, Isabel Y., Hayes, Christine, Dimmick, Jason, Morgan, B. Paul, Holers, V. Michael, Marchbank, Kevin J.
Publicado no Immunobiology (2011)

Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice

Por Twohig, Jason P., Pappworth, Isabel Y., Sivasankar, Baalasubramanian, Kulik, Liudmila, Bull, Melanie, Holers, V. Michael, Wang, Eddie C.Y., Marchbank, Kevin J.
Publicado em 2009

An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy

Por Nichols, Eva-Maria, Barbour, Thomas D, Pappworth, Isabel Y, Wong, Edwin K S, Palmer, Jeremy M, Sheerin, Neil S, Pickering, Matthew C, Marchbank, Kevin J
Publicado no Kidney Int (2015)

A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice

Por He, Yong-Gang, Pappworth, Isabel Y., Rossbach, Andreas, Paulin, Joshua, Mavimba, Tarirai, Hayes, Christine, Kulik, Liudmila, Holers, V.Michael, Knight, Andrew M., Marchbank, Kevin J.
Publicado no Immunobiology (2018)

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

Por Moore, Iain, Strain, Lisa, Pappworth, Isabel, Kavanagh, David, Barlow, Paul N., Herbert, Andrew P., Schmidt, Christoph Q., Staniforth, Scott J., Holmes, Lucy V., Ward, Roy, Morgan, Lynn, Goodship, Timothy H. J., Marchbank, Kevin J.
Publicado em 2010

Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?

Por Kavanagh, David, Pappworth, Isabel Y., Anderson, Holly, Hayes, Christine M., Moore, Iain, Hunze, Eva-Maria, Bennaceur, Karim, Roversi, Pietro, Lea, Susan, Strain, Lisa, Ward, Roy, Plant, Nick, Nailescu, Corina, Goodship, Timothy H. J., Marchbank, Kevin J.
Publicado em 2012

Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS)

Por Watson, Rachael, Wearmouth, Emma, McLoughlin, Amy-Claire, Jackson, Arthur, Ward, Sophie, Bertram, Paula, Bennaceur, Karim, Barker, Catriona E., Pappworth, Isabel Y., Kavanagh, David, Lea, Susan M., Atkinson, John P., Goodship, Timothy H.J., Marchbank, Kevin J.
Publicado no Mol Immunol (2014)

Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients

Por Schmidt, Christoph Q., Harder, Markus J., Nichols, Eva-Maria, Hebecker, Mario, Anliker, Markus, Höchsmann, Britta, Simmet, Thomas, Csincsi, Ádám I., Uzonyi, Barbara, Pappworth, Isabel Y., Ricklin, Daniel, Lambris, John D., Schrezenmeier, Hubert, Józsi, Mihály, Marchbank, Kevin J.
Publicado no Immunobiology (2016)